Tiziana Life Sciences Ltd. (NASDAQ:TLSA) has taken a major step towards addressing Secondary Progressive Multiple Sclerosis (SPMS) by initiating Phase 2a clinical trials for its intranasal foralumab program. The company recently hosted an Investigator's Meeting in collaboration with principal investigators from Brigham and Women’s Hospital, a founding member of the Mass General Brigham Healthcare System, to commence site initiation for this pivotal research.

• Tiziana Life Sciences is advancing its lead intranasal foralumab program into Phase 2a clinical testing, specifically targeting non-active SPMS (na-SPMS) patients.
• The company aims to recruit six to ten new clinical trial sites to bolster the research initiative.
• Dr. Matthew W. Davis, Chief Operating Officer and Chief Medical Officer of Tiziana Life Sciences, affirmed the project's progress and the initiation of site visits, marking the start of patient enrollment.
• The Phase 2a trials offer an opportunity to define novel endpoints, including PET imaging, building on insights gained from the Expanded Access program (EAP).
• Encouraging results from the EAP, with five out of six patients showing PET scan improvements after three months of treatment, provide optimism for the upcoming Phase 2a trials.
• Importantly, this marks the first time a double-blind, randomized placebo-controlled, multi-center trial is being conducted for this innovative therapeutic.
• Tiziana Life Sciences' dedication to advancing therapeutic solutions for SPMS patients underscores their commitment to making a meaningful impact in the fight against this challenging condition.